| Bioactivity | Promegestone (R-5020), a progestin, is a potent progesterone receptor (PR) agonist. Promegestone has the potential for endocrine regulation and cancer research[1]. |
| Invitro | Promegestone (R-5020; 1 nM) is efficient ligand with a full agonist response profile and a low EC50 of 0.33 nM) in HELN-hPR while it only partially induced luciferase activity in U2OS-zfPR (EC50=1.93 nM)[1]. Promegestone is inactive in HELN cells that express luciferase but no functional receptor[1]. Promegestone (10 nM) robustly stimulates SLC37A2 expression in cells expressing SUMO-deficient PR, but not in cells expressing WT PR in T47D cell models[3]. |
| In Vivo | Promegestone (R-5020; 8 mg/kg; intramuscularly)-treated pregnant mice on day 18 postbreeding has the least deterioration in extracellular collagen (lowest OD) and highest cell density compared to other groups on the day before birth[2]. |
| Name | Promegestone |
| CAS | 34184-77-5 |
| Formula | C22H30O2 |
| Molar Mass | 326.47 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Clémentine Garoche, et al. Human and Zebrafish Nuclear Progesterone Receptors Are Differently Activated by Manifold Progestins. Environ Sci Technol. 2020 Aug 4;54(15):9510-9518. [2]. Michael A Kirby, et al. Progesterone Receptor-Mediated Actions Regulate Remodeling of the Cervix in Preparation for Preterm Parturition. Reprod Sci. 2016 Nov;23(11):1473-1483. [3]. Todd P Knutson, et al. Posttranslationally modified progesterone receptors direct ligand-specific expression of breast cancer stem cell-associated gene programs. J Hematol Oncol. 2017 Apr 17;10(1):89. |